A Immuno Series 
Webinar

The CAM Assay: From Efficacy/Toxicity Studies to Mechanisms of Action Analysis

Presented by Xavier Rousset, PhD, Research Scientist, Inovotion

18 November 2021 at 15:00 |

GMT (UTC+0)

Understanding the mechanisms of action of new drugs is a key success factor for efficient drug discovery. It’s necessary for: 

  • Anticipating problems relating to clinical safety 
  • Determining the site of interaction between a drug and a receptor 
  • Identifying which patients will respond to a given treatment  
  • Improving drug dosing  
  • Considering combinations or synergistic effects 

Thus, understanding the mechanisms of action is needed at all steps in the drug development pipeline, from discovery to clinical trials and regulatory approval.  

Inovotion’s in vivo assays provide ample access to tumors, allowing a deep analysis of its mechanisms of action including transcriptomics, metabolomics, proteomics, immune cell infiltration, histological analysis, target validation, and others.  

During the webinar, Xavier Rousset will discuss:  

  • Benefits of the in ovo model for with human tumors for understanding mechanisms of action  
  • Chicken embryo model and its characteristics 
  • Considerations for setting up the assay: Pharmaco-Kinetics (PK), Maximal Tolerated Dose (MTD), Minimum Effective Dose (MED), Dose Effect 
  • Access to mechanisms of action through transcriptomic, proteomic and metabolomic analyses 
  • Method for target validation using the in ovo model 
  • Rapid analysis for immunohistology, biomarkers, immune cell infiltration 
  • Case studies

Learning Objectives: 

  • Benefits of setting up an early in vivo efficacy evaluation and mechanisms of action analysis to optimize the probability of success for drug discovery development 
  • Using the chicken embryo in vivo model to get access to a drug’s mechanisms of action   
  • Understand the characteristics of the chicken embryo model versus the mouse model 

Speaker: Xavier Rousset, PhD, Research Scientist, Inovotion 

Xavier is the head of Inovotion's R&D department. He joined Inovotion at its creation in 2015 and oversees the development of new tests and readouts. He leads client projects and initiates technological improvements to meet specific customer requests. 

Xavier has extended Inovotion's tests to cover Immuno-Oncology. He has developed dozens of new cancer models and set up standardized data sets for their associated reference molecules. 

Xavier earned his PhD in physiology and physiopathology at the University Pierre et Marie Curie of Paris, working on lipid metabolism. He then held several postdoctoral positions in the USA at the NIH National Heart, Lung and Blood Institute in Bethesda and in France (Université Grenoble Alpes) moving to cancer research. 

We produce cutting edge congresses and summits for the Life Sciences Industry, bringing together industry leaders and solution providers at a senior level, creating the opportunity to partner, network and knowledge share.

Contact Us:

Copyright Oxford Global Marketing Limited. All rights reserved.

Stay up to date

Sign up for our monthly Editorial Newsletter to keep up with all things Immuno

Submit your details to receive the monthly newsletter & to be kept up to date about relevant events, monthly discussion groups and portal membership offers. You may opt-out at any time. Please check our Privacy Policy to see how Oxford Global protects and manages your data.

Thank you for your query

A member of our team will be in touch soon